<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Clin Invest</journal-id>
<journal-id journal-id-type="iso-abbrev">J. Clin. Invest</journal-id>
<journal-id journal-id-type="publisher-id">J Clin Invest</journal-id>
<journal-title-group>
<journal-title>The Journal of Clinical Investigation</journal-title>
</journal-title-group>
<issn pub-type="ppub">0021-9738</issn>
<issn pub-type="epub">1558-8238</issn>
<publisher>
<publisher-name>American Society for Clinical Investigation</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31094705</article-id>
<article-id pub-id-type="pmc">6668686</article-id>
<article-id pub-id-type="publisher-id">127411</article-id>
<article-id pub-id-type="doi">10.1172/JCI127411</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Autism-linked dopamine transporter mutation alters striatal dopamine neurotransmission and dopamine-dependent behaviors</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-3974-0105</contrib-id>
<name>
<surname>DiCarlo</surname>
<given-names>Gabriella E.</given-names>
</name>
<email>gabriella.e.dicarlo@vanderbilt.edu</email>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-7533-5153</contrib-id>
<name>
<surname>Aguilar</surname>
<given-names>Jenny I.</given-names>
</name>
<email>jenny.i.aguilar@vanderbilt.edu</email>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Matthies</surname>
<given-names>Heinrich J.G.</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-1121-0647</contrib-id>
<name>
<surname>Harrison</surname>
<given-names>Fiona E.</given-names>
</name>
<email>Fiona.harrison@vanderbilt.edu</email>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bundschuh</surname>
<given-names>Kyle E.</given-names>
</name>
<email>kyle.e.bundschuh@vanderbilt.edu</email>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>West</surname>
<given-names>Alyssa</given-names>
</name>
<email>amwest@email.sc.edu</email>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hashemi</surname>
<given-names>Parastoo</given-names>
</name>
<email>HASHEMI@mailbox.sc.edu</email>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-0159-4598</contrib-id>
<name>
<surname>Herborg</surname>
<given-names>Freja</given-names>
</name>
<email>frejahh@sund.ku.dk</email>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rickhag</surname>
<given-names>Mattias</given-names>
</name>
<email>rickhag@sund.ku.dk</email>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Hao</given-names>
</name>
<email>hao.chen@dribiosciencescorp.com</email>
<xref ref-type="aff" rid="A7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gether</surname>
<given-names>Ulrik</given-names>
</name>
<email>gether@sund.ku.dk</email>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-0166-906X</contrib-id>
<name>
<surname>Wallace</surname>
<given-names>Mark T.</given-names>
</name>
<email>mark.wallace@vanderbilt.edu</email>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A8">8</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Galli</surname>
<given-names>Aurelio</given-names>
</name>
<email>agalli@uab.edu</email>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Vanderbilt University Brain Institute, Nashville, Tennessee, USA.</aff>
<aff id="A2"><label>2</label>Department of Pharmacology, Vanderbilt University, Nashville, Tennessee, USA.</aff>
<aff id="A3"><label>3</label>Department of Surgery, University of Alabama at Birmingham, Birmingham, Alabama, USA.</aff>
<aff id="A4"><label>4</label>Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.</aff>
<aff id="A5"><label>5</label>Department of Chemistry and Biochemistry, University of South Carolina, Columbia, South Carolina, USA.</aff>
<aff id="A6"><label>6</label>Molecular Neuropharmacology and Genetics Laboratory, Department of Neuroscience, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</aff>
<aff id="A7"><label>7</label>DRI Biosciences Corp., Frederick, Maryland, USA.</aff>
<aff id="A8"><label>8</label>Department of Hearing and Speech Sciences, Vanderbilt University, Nashville, Tennessee, USA.</aff>
<author-notes>
<corresp>Address correspondence to: Aurelio Galli, 1032 Tinsley Harrison Tower, 1900 University Boulevard, Birmingham, Alabama 35233, USA. Phone: 205.975.1932; Email: <email>agalli@uab.edu</email>. Or to: Mark Wallace, 465 21st Avenue South, MRB III Suite 7110, Nashville, Tennessee 37240, USA. Phone: 615.936.7108; Email: <email>mark.wallace@vanderbilt.edu</email>.</corresp>
<fn>
<p><bold>Authorship note:</bold> UG, MTW, and AG contributed equally to this work.</p>
</fn>
<fn fn-type="COI-statement">
<p><bold>Conflict of interest:</bold> HC is the president and CSO of DRI Biosciences Corporation that is developing treatments for neurological disorders including Fragile X Syndrome and Autism Spectrum Disorder.</p>
</fn>
</author-notes>
<pub-date date-type="pub" iso-8601-date="2019-07-22T16:00:00-0400" publication-format="electronic">
<day>22</day>
<month>7</month>
<year>2019</year>
</pub-date>
<pub-date date-type="collection" iso-8601-date="2019-07-22T16:00:00-0400" publication-format="electronic">
<day>22</day>
<month>7</month>
<year>2019</year>
</pub-date>
<pub-date date-type="pub" iso-8601-date="2019-08-01T16:00:00-0400" publication-format="print">
<day>1</day>
<month>8</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>1</day>
<month>11</month>
<year>2019</year>
</pub-date>
<!-- PMC Release delay is 3 months and
						0 days and was based on the <pub-date
						pub-type="ppub"/>. -->
<volume>129</volume>
<issue>8</issue>
<fpage>3407</fpage>
<lpage>3419</lpage>
<history>
<date date-type="received">
<day>14</day>
<month>1</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>10</day>
<month>5</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>Â© 2019 American Society for Clinical Investigation</copyright-statement>
<copyright-year>2019</copyright-year>
<copyright-holder>American Society for Clinical Investigation</copyright-holder>
</permissions>
<self-uri xlink:href="https://www.jci.org/articles/view/127411">This article is available online at https://www.jci.org/articles/view/127411</self-uri>
<abstract>
<p>The precise regulation of synaptic dopamine (DA) content by the DA transporter (DAT) ensures the phasic nature of the DA signal, which underlies the ability of DA to encode reward prediction error, thereby driving motivation, attention, and behavioral learning. Disruptions to the DA system are implicated in a number of neuropsychiatric disorders, including attention deficit hyperactivity disorder (ADHD) and, more recently, autism spectrum disorder (ASD). An ASD-associated de novo mutation in the <italic>SLC6A3</italic> gene resulting in a threonine-to-methionine substitution at site 356 (DAT T356M) was recently identified and has been shown to drive persistent reverse transport of DA (i.e., anomalous DA efflux) in transfected cells and to drive hyperlocomotion in <italic>Drosophila melanogaster</italic>. A corresponding mutation in the leucine transporter, a DAT-homologous transporter, promotes an outward-facing transporter conformation upon substrate binding, a conformation possibly underlying anomalous DA efflux. Here, we investigated in vivo the impact of this ASD-associated mutation on DA signaling and ASD-associated behaviors. We found that mice homozygous for this mutation displayed impaired striatal DA neurotransmission and altered DA-dependent behaviors that correspond with some of the behavioral phenotypes observed in ASD.</p>
</abstract>
<kwd-group kwd-group-type="specialties">
<kwd>Neuroscience</kwd>
</kwd-group>
<kwd-group kwd-group-type="keywords">
<kwd>Molecular biology</kwd>
<kwd>Psychiatric diseases</kwd>
<kwd>Transport</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>
<institution-wrap>
<institution>National Institutes of Health</institution>
<institution-id>https://doi.org/10.13039/100000002</institution-id>
</institution-wrap>
</funding-source>
<award-id>R01DA038058</award-id>
</award-group>
<award-group>
<funding-source>
<institution-wrap>
<institution>National Institutes of Health</institution>
<institution-id>https://doi.org/10.13039/100000002</institution-id>
</institution-wrap>
</funding-source>
<award-id>F30MH115535</award-id>
</award-group>
<award-group>
<funding-source>
<institution-wrap>
<institution>National Institutes of Health</institution>
<institution-id>https://doi.org/10.13039/100000002</institution-id>
</institution-wrap>
</funding-source>
<award-id>F31MH114316</award-id>
</award-group>
<award-group>
<funding-source>
<institution-wrap>
<institution>National Institutes of Health</institution>
<institution-id>https://doi.org/10.13039/100000002</institution-id>
</institution-wrap>
</funding-source>
<award-id>T32GM007347</award-id>
</award-group>
<award-group>
<funding-source>
<institution-wrap>
<institution>National Institutes of Health</institution>
<institution-id>https://doi.org/10.13039/100000002</institution-id>
</institution-wrap>
</funding-source>
<award-id>U54HD083211</award-id>
</award-group>
<award-group>
<funding-source>Vanderbilt Kennedy Center for Excellence in Developmental Disabilities</funding-source>
<award-id>90DD0595</award-id>
</award-group>
<award-group>
<funding-source>
<institution-wrap>
<institution>National Institutes of Health</institution>
<institution-id>https://doi.org/10.13039/100000002</institution-id>
</institution-wrap>
</funding-source>
<award-id>R01DA35263</award-id>
</award-group>
<award-group>
<funding-source>
<institution-wrap>
<institution>National Institutes of Health</institution>
<institution-id>https://doi.org/10.13039/100000002</institution-id>
</institution-wrap>
</funding-source>
<award-id>R01MH106563</award-id>
</award-group>
</funding-group>
</article-meta>
</front>
</article>
</pmc-articleset>